enGene Therapeutics Reports $30.2 Million Net Loss for Q2 2026, Expands LEGEND Clinical Trial

enGene Therapeutics Inc. reported a net loss of $30.2 million for the three months ended April 30, 2026, compared to a loss of $25.8 million for the same period in 2025. For the six months ended April 30, 2026, the company recorded a net loss of $60.0 million, up from $50.4 million in the prior year. The increase in losses is attributed to higher operating expenses, which rose to $32.0 million in the latest quarter from $27.1 million a year earlier, driven primarily by increased research and development costs associated with the ongoing LEGEND clinical trial for its lead product candidate, detalimogene voraplasmid.

The company's total operating expenses for the first half of 2026 reached $63.2 million, compared to $53.7 million in the same period of 2025. Research and development expenses accounted for a significant portion of these costs, totaling $44.5 million for the six months ended April 30, 2026, an increase of $4.3 million from the previous year. General and administrative expenses also rose, reflecting the company's efforts to scale operations and support its clinical activities.

In terms of strategic developments, enGene has expanded its LEGEND trial to include a new cohort that incorporates a surfactant bladder rinse prior to the administration of detalimogene. This trial is crucial as it aims to address the unmet medical needs of patients with BCG-unresponsive non-muscle invasive bladder cancer. The company has completed enrollment for the pivotal cohort of the trial, which includes 125 patients, and anticipates submitting a Biologics License Application (BLA) to the FDA in the second half of 2026.

As of April 30, 2026, enGene reported cash, cash equivalents, and marketable securities totaling $285.2 million, a significant increase from $202.3 million at the end of October 2025. This increase is largely due to a public offering that raised approximately $140.1 million in net proceeds. However, the company has also announced a workforce reduction of approximately 50% to streamline operations and conserve cash, which is expected to incur restructuring costs of between $5.7 million and $6.4 million.

Looking ahead, enGene's management expects that its existing cash reserves will be sufficient to fund operations for at least the next 12 months. However, the company acknowledges the need for additional funding to support ongoing clinical trials and operational activities. The successful development and commercialization of detalimogene remain uncertain, and the company may seek further financing through equity offerings, debt arrangements, or strategic partnerships to ensure its long-term viability.